Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.
The investigators aim to learn how adipocyte dysfunction and disordered fat distribution contribute to the development of type 2 diabetes in normal-weight individuals. The investigators hope to determine whether adipocyte-directed therapies, such as pioglitazone and tirzepatide, can improve insulin sensitivity, fat distribution, and metabolic health in this population. This study is important because most diabetes research focuses on overweight or obese individuals, and very little is known about how diabetes affects those with normal body weight. Understanding the unique biology of normal-weight diabetes could lead to more personalized and effective treatment strategies, filling a gap in diabetes care for a group that can be overlooked in clinical research.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Normal weight controls | Other | Control |
|
| Normal weight with diabetes tirzepatide first pioglitazone second | Experimental | Baseline testing Intervention with tirzepatide for 16 weeks Retesting Washout for 5 weeks Intervention with pioglitazone for 16 weeks Retesting |
|
| Normal weight with diabetes pioglitazone first, tirzepatide second | Experimental | Baseline testing Intervention with pioglitazone for 16 weeks Retesting Washout for 5 weeks Intervention with tirzepatide for 16 weeks Retesting |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Insulin resistance testing | Procedure | Steady state Plasma Glucose test |
|
| Measure | Description | Time Frame |
|---|---|---|
| Insulin resistance in normal weight women with diabetes compared to those with no diabetes | Insulin resistance will be measured by a Steady State Plasma Glucose test (SSPG). Results will be measured by glucose levels at steady state in mg/dL. | Baseline measures comparison between the groups |
| Adipocyte function in women with normal weight diabetes as compared with those without diabetes | Adipocyte function will be measured as percent small adipocytes and peak diameter adipocytes from the fat biopsies. | Baseline comparisons |
| Fat storage in women with normal weight diabetes compared to those without diabetes | Fat storage will be measured by MRI. Quantification of subcutaneous and visceral abdominal fat will be obtained by MRI using a fat-water imaging sequence (parameters: IDEAL-IQ: 3D GRE, 160x160 matrix, 6 echoes, 4 degree flip angle, minimum TR = 7.3 ms, 28 slices, 10 mm slice thickness. | Baseline comparisons between the groups |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of adipose-directed therapy pioglitazone on HbA1c in both men and women with normal weight diabetes | Hemoglobin A1C measures will be compared baseline to end of 16 weeks of intervention with pioglitazone. | 16 weeks |
| Effect of pioglitazone in insulin resistance in both men and women. |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of adipose-directed therapy with tirzepatide on insulin resistance in men and women with normal weight diabetes (NWD). | SSPG test results will be compared from baseline to end of tirzepatide intervention. Results will be measured by glucose levels at steady state in mg/dL. | 16 weeks |
Inclusion Criteria:
Normal-Weight Diabetes (NWD) Group:
Normal-Weight Control (NWC) Group:
Exclusion Criteria:
Pregnancy or Lactation: Women who are pregnant, planning to become pregnant, or breastfeeding are excluded due to potential risks to the fetus or infant.
Prior Use of Pioglitazone: Participants who have previously used pioglitazone are excluded to avoid confounding effects of prior drug exposure.
Unstable Body Weight: Individuals with a body weight change of more than 2 kg in the last 3 months are excluded to ensure stable metabolic conditions.
Liver or Kidney Disease: Participants with significant liver disease (ALT > 3x upper limit of normal) or renal disease (creatinine > 1.5 mg/dL) are excluded due to potential safety risks.
Congestive Heart Failure or Fluid Overload History: These conditions are exclusionary due to the risk of fluid retention with pioglitazone.
Uncontrolled Hypertension: Blood pressure > 160/90 mmHg excludes participants due to increased cardiovascular risk.
Active Cancer: Individuals with a diagnosis of cancer in the past 3 years (except for skin cancer) are excluded.
Chronic Inflammatory Diseases: Excluded due to potential effects on metabolic measurements.
Use of Weight Loss Medications: Those currently taking weight loss medications are excluded to prevent confounding effects on body weight and metabolic function.
Bariatric Surgery or Liposuction History: Participants who have had weight-loss surgeries or liposuction are excluded due to alterations in fat tissue and metabolic profiles.
Insulin Use: Participants using insulin are excluded to focus on non-insulin-dependent diabetes.
Active Psychiatric Disease or Eating Disorders: Individuals with these conditions are excluded due to potential impacts on study compliance and data integrity.
Substance Abuse: Participants with a history of substance abuse are excluded for similar reasons.
-
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nina Shenoy, BS | Contact | 408-896-0134 | nshenoy8@stanford.edu | |
| Alisa Turner, BS | Contact | 650-285-8855 | alturner@stanford.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Recruiting | Palo Alto | California | 94304 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Control groups will undergo baseline testing to provide information about people without diabetes, but will not proceed with treatment.
Not provided
Not provided
Not provided
Not provided
|
| OGTT | Procedure | Will collect 5 blood draws during the test to measure insulin secretion |
|
|
| Fat biopsy | Procedure | Needle biopsy to gather a sample of abdominal subcutaneous fat |
|
| DXA scan | Radiation | Whole body DXA scan |
|
| MRI | Procedure | Abdominal MRI |
|
| 1H-MRS | Procedure | Spectroscopy of the abdominal region |
|
|
| Tirzepatide | Drug | 16 weeks started at 2.5mg/week and increased to 5mg/week dose |
|
|
| Pioglitazone | Drug | 16 weeks at a 45mg/day dose |
|
|
SSPG test results will be compared from baseline to end of pioglitazone intervention. Results will be measured by glucose levels at steady state in mg/dL. |
| 16 weeks |
| Fat storage in men with normal weight diabetes (NWD) compared to those without diabetes (NWC). | Fat storage will be measured by MRI. Quantification of subcutaneous and visceral abdominal fat will be obtained by MRI using a fat-water imaging sequence (parameters: IDEAL-IQ: 3D GRE, 160x160 matrix, 6 echoes, 4 degree flip angle, minimum TR = 7.3 ms, 28 slices, 10 mm slice thickness. | Baseline comparisons between the groups |
| Adipocyte function in men with normal weight diabetes as compared with those without diabetes | Adipocyte function as measured by percent small adipocytes and peak diameter adipocytes from the fat biopsies. | Baseline comparisons |
| Insulin resistance in normal weight men with diabetes compared to those with no diabetes | Insulin resistance will be measured by a Steady State Plasma Glucose test (SSPG). Results will be measured by glucose levels at steady state in mg/dL. | Baseline measures comparison between the groups |
| Insulin secretion in men and women with normal weight diabetes compared to those without diabetes | A five-point, three-hour OGTT will be done after overnight fast for calculation of insulin secretion using c-peptide deconvolution, and disposition index calculated by dividing this value by SSPG. | Baseline measured compared between the groups |
| Stanford University, Clinical and Translational Research Unit (CTRU) | Not yet recruiting | Stanford | California | 94304 | United States |
|
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D003920 | Diabetes Mellitus |
| D018149 | Glucose Intolerance |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D006943 | Hyperglycemia |
| D006946 | Hyperinsulinism |
Not provided
Not provided
| ID | Term |
|---|---|
| D005951 | Glucose Tolerance Test |
| D015502 | Absorptiometry, Photon |
| D066244 | Proton Magnetic Resonance Spectroscopy |
| D000098860 | Tirzepatide |
| D000077205 | Pioglitazone |
| ID | Term |
|---|---|
| D001774 | Blood Chemical Analysis |
| D019963 | Clinical Chemistry Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D003940 | Diagnostic Techniques, Endocrine |
| D008919 | Investigative Techniques |
| D011859 | Radiography |
| D003952 | Diagnostic Imaging |
| D003720 | Densitometry |
| D010783 | Photometry |
| D002623 | Chemistry Techniques, Analytical |
| D009682 | Magnetic Resonance Spectroscopy |
| D013057 | Spectrum Analysis |
| D000067757 | Glucagon-Like Peptide-1 Receptor |
| D000067756 | Glucagon-Like Peptide Receptors |
| D043562 | Receptors, G-Protein-Coupled |
| D011956 | Receptors, Cell Surface |
| D008565 | Membrane Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011964 | Receptors, Gastrointestinal Hormone |
| D018000 | Receptors, Peptide |
| D045162 | Thiazolidinediones |
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided